ESR1 and neoplasm: At present, immunohistochemical (IHC) testing is most frequently used to assign tumor ER-status, where antibodies directed against the ER protein are applied to formalin-fixed, paraffin-embedded tumor samples, and the abundance of ER is determined semi-quantitatively by light microscopy.